info@mail.ucallm.com
From Cellular Reprogramming to Therapeutic Differentiation — Empowering Precision PSC Characterization, Lineage Specification, and Cell Therapy Development with Validated Antibody Solutions
Human pluripotent stem cells (hPSCs), including human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs), combine long-term self-renewal with broad differentiation potential, providing versatile platforms for developmental biology, disease modeling, drug discovery, regenerative medicine, and cell-based therapies.
The generation of reliable PSC-derived cell products requires more than confirmation of pluripotency. Researchers must establish a continuous molecular and functional profile spanning cell identity, reprogramming quality, genomic and epigenetic stability, lineage commitment, differentiation efficiency, cellular maturation, functional phenotype, and safety.
Successful PSC research and clinical translation require comprehensive molecular characterization across multiple stages:
· Maintenance of pluripotency and self-renewal state
· Reprogramming factor activation and epigenetic resetting
· Directed lineage differentiation
· Immune compatibility and transplantation safety
· Genome editing validation and quality control
· Tumorigenicity risk assessment
· Functional maturation of therapeutic cell products
Our validated antibody portfolio enables researchers to monitor PSC identity, differentiation trajectories, cellular engineering outcomes, and therapeutic product quality through:
· Pluripotency marker profiling
· Lineage-specific differentiation validation
· Stem cell-derived therapeutic cell characterization
· Immune recognition and transplantation assessment
· Genome editing and engineered cell verification
· Signaling pathway analysis during differentiation
PSC Identity & Pluripotency Biomarker Antibody Portfolio
—Comprehensive Antibody Solutions for Pluripotent Stem Cell Identification, Reprogramming Validation, Epigenetic Resetting, and Differentiation Potential Assessment
Pluripotency is maintained through a tightly regulated transcriptional network involving core reprogramming factors, epigenetic regulators, and surface-associated stem cell markers.
Our antibody solutions support reliable identification of undifferentiated PSC populations and evaluation of reprogramming efficiency.
Research Focus | Representative Biomarkers | Biological Significance | Antibody Research Applications |
Core Pluripotency Transcription Network | OCT4 (POU5F1), SOX2, NANOG | Central transcriptional circuitry maintaining embryonic stem cell identity, self-renewal capacity, and suppression of lineage differentiation programs | Identification of undifferentiated hESC/hiPSC populations; validation of pluripotency maintenance by IF, WB, IHC |
Yamanaka Reprogramming Factors | OCT4, SOX2, KLF4, c-MYC | Defined factors driving somatic cell reprogramming through activation of stemness-associated transcriptional programs and epigenetic resetting | Monitoring iPSC generation efficiency; characterization of reprogramming intermediates; evaluation of induced pluripotent states |
Pluripotency Surface Marker Panel | TRA-1-60, TRA-1-81, SSEA-4, SSEA-3, SSEA-1 | Cell-surface glycoprotein and glycolipid markers associated with undifferentiated human PSC populations | Flow cytometry-based PSC identification, sorting, enrichment, and quality assessment |
Self-Renewal & Stem Cell Maintenance Signaling | LIF/STAT3 axis: STAT3, p-STAT3; Wnt/β-catenin pathway: β-catenin, GSK3β; FGF/ERK pathway: FGFR1, ERK1/2 | Signaling networks regulating PSC proliferation, survival, metabolic state, and differentiation balance | Analysis of PSC culture conditions, signaling activation, and maintenance mechanisms |
Epigenetic Pluripotency Regulation | TET1, TET2, TET3; DNMT1, DNMT3A/B; EZH2; H3K27me3; H3K4me3; H3K9me3 | Chromatin remodeling and DNA methylation dynamics responsible for epigenetic resetting during reprogramming and lineage restriction | Investigation of epigenetic memory, chromatin accessibility, and PSC fate transitions |
Nuclear Architecture & Genome Stability | Lamin A/C, γH2AX, RAD51, ATM, ATR, p53 | Maintenance of genome integrity during prolonged PSC expansion and differentiation processes | PSC quality control, genomic stability assessment, and DNA damage response analysis |
Metabolic State Transition Markers | SIRT1, SIRT3, AMPKα, HIF1α, PGC-1α, TOM20, COX IV | PSCs undergo metabolic remodeling between glycolytic pluripotent states and oxidative differentiated states | Characterization of metabolic reprogramming during pluripotency maintenance and differentiation |
PSC-Derived Cell Therapy Quality Control Panel
—Ensuring Identity, Purity, Safety, and Functional Maturation of Therapeutic Cell Products
Clinical translation of PSC-derived therapies requires rigorous assessment of:
· Correct lineage specification
· Residual undifferentiated PSC elimination
· Immune compatibility
· Genetic engineering accuracy
· Tumorigenic risk control
Quality Control Category | Representative Targets | Research Application |
Residual PSC Detection | OCT4, NANOG, TRA-1-60, SSEA-4 | Detection of undifferentiated contaminating cells |
Cell Identity Validation | Lineage-specific markers | Confirmation of therapeutic cell phenotype |
Immune Compatibility | HLA-A/B/C, HLA-E, β2M, HLA-DR、HLA-DP、HLA-DQ | Evaluation of immune recognition and transplantation compatibility |
Genome Editing Validation | Cas9, GFP reporter, FLAG-tag | Verification of engineered PSC lines |
Safety Monitoring | Ki67, p53, p21, c-MYC | Proliferation and tumorigenicity assessment |
PSC Signaling Pathway Research Panel
—Decoding Molecular Signals Driving Self-Renewal, Differentiation, and Cell Fate Decisions
PSC fate transitions are controlled by conserved developmental pathways:
Signaling Axis | Key Targets | Biological Function |
Wnt/β-catenin | β-catenin, GSK3β, TCF/LEF | Mesoderm induction and lineage specification |
TGF-β/Nodal | TGFβ1, SMAD2/3, SMAD4 | Maintenance of pluripotency and differentiation |
BMP Signaling | BMP4, p-SMAD1/5/9 | Mesoderm and trophoblast differentiation |
FGF/ERK Pathway | FGFR, ERK1/2, p-ERK | Proliferation and lineage progression |
Notch Signaling | NOTCH1, NICD, HES1 | Neural and developmental fate regulation |
Featured PSC Differentiation Research Panels
—Comprehensive Antibody Panels for Lineage Commitment, Functional Maturation, and Regenerative Medicine Applications
Directed differentiation of PSCs requires precise monitoring of lineage-specific transcription factors, structural proteins, and functional maturation markers.
n Neural & Neurodegenerative Disease Modeling Panel
Neural progenitor generation, spinal cord repair, neurological disease modeling
Cell Stage | Key Markers |
Neural induction | PAX6, SOX1, SOX2 |
Neural progenitor | NESTIN, SOX2, MUSASHI-1 |
Neuron maturation | TUJ1/TUBB3, MAP2, NeuN/RBFOX3 |
Dopaminergic neuron | TH, FOXA2, LMX1A |
Oligodendrocyte lineage | OLIG2, NG2/CSPG4, MBP |
n Cardiac Differentiation Panel
PSC-derived cardiomyocyte production, heart regeneration, drug screening
Differentiation Stage | Biomarkers |
Mesoderm induction | BRACHYURY/T, MIXL1 |
Cardiac progenitor | NKX2.5, ISL1 |
Cardiomyocyte identity | TNNT2/cTnT, ACTN2, MYH6 |
Functional maturation | MYL2, RYR2, SERCA2 |
n Mesoderm & Mesenchymal Lineage Panel
Bone, cartilage, vascular, and connective tissue differentiation
Lineage | Markers |
Mesoderm | BRACHYURY, MIXL1 |
MSC identity | CD73, CD90, CD105 |
Osteogenic differentiation | RUNX2, SP7/Osterix, ALPL |
Chondrogenic differentiation | SOX9, COL2A1, ACAN |
Why Researchers Choose Our PSC & Reprogramming Antibody Solutions
Validated Pluripotency Markers. Comprehensive Differentiation Panels. Reliable Cell Therapy Insights.
Our antibody portfolio supports complete PSC research workflows:
Research Challenge | Antibody Solution |
How can I confirm PSC identity? | OCT4, SOX2, NANOG, TRA-1-60, SSEA-4 pluripotency panel |
How can I evaluate reprogramming efficiency? | OCT4, KLF4, c-MYC, epigenetic remodeling markers |
How can I monitor lineage differentiation? | Neural, cardiac, retinal, mesenchymal lineage-specific marker panels |
How can I ensure therapeutic cell purity? | Residual PSC detection and lineage validation markers |
How can I evaluate transplantation compatibility? | HLA, β2M, immune recognition markers |
How can I validate engineered PSC models? | Cas9, reporter proteins, epitope-tag detection |
How can I perform spatial characterization? | Multiplex IF/IHC-compatible validated antibody solutions |
Key reference
1. Yamanaka S., Mandai M., Takahashi K. (2024). Clinical translation of human pluripotent stem cell therapies: progress, barriers and regulatory landscape. Nat Rev Drug Discov. 23: 689–712.
2. Studer L., Tabar V. (2023). Lineage specification of human pluripotent stem cells: signaling and biomarker landscape. Cell Stem Cell. 30: 1125–1146.
3. Movahed A.Y., Bagheri R., Savatier P., Šarić T., Moradi S. (2025). Elimination of tumorigenic pluripotent stem cells from their differentiated cell therapy products. Stem Cell Reports. 10: 102543.
4. Kikuchi H., Mandai M. (2022). Human iPSC-derived cell therapeutics for degenerative diseases. Annu Rev Med. 73: 527–543.